Corrigendum to "American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction" [Gynecol. Oncol. 115 (2009) 132-134] (DOI:10.1016/j.ygyno.2009.06.006);American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction

Gynecologic Oncology

Volumn 115, Issue 1, 2009, Pages 132-134

  Temin, Sarah ^a  

^a AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE; AROMATASE INHIBITOR; ESTROGEN RECEPTOR; FENRETINIDE; RALOXIFENE; TAMOXIFEN;

ARTICLE; BLADDER DYSFUNCTION; BREAST CANCER; CANCER PREVENTION; CANCER RISK; CATARACT; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COGNITION; DEEP VEIN THROMBOSIS; DRUG INDICATION; DRUG SAFETY; DYSPAREUNIA; GYNECOLOGIC DISEASE; HEALTH CARE DISPARITY; HOT FLUSH; HUMAN; LUNG EMBOLISM; MEDICAL SOCIETY; MUSCLE CRAMP; MUSCULOSKELETAL DISEASE; PERIPHERAL EDEMA; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK REDUCTION; SIDE EFFECT; STROKE; SYSTEMATIC REVIEW; THROMBOPHLEBITIS; TRANSIENT ISCHEMIC ATTACK; UNITED STATES; URINE INCONTINENCE; VAGINA BLEEDING; VASOMOTOR DISORDER; VENOUS THROMBOEMBOLISM;

EID: 69149087312     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.12.019     Document Type: Erratum

References (2)

1. Visvanathan K., Chlebowski R.T., Hurley P., et al. American Society of Clinical Oncology Clinical Practice Guideline Update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J. Clin. Oncol. 27 (2009) 3235-3258
2. [2] National Cancer Institute: Breast Cancer Risk Assessment Tool. http://www.cancer.gov/bcrisktool